MINNEAPOLIS--(BUSINESS WIRE)--Pelvital, a privately held medical device company that has developed Flyte™, a clinically proven, FDA-cleared, non-surgical treatment for female stress urinary incontinence, announced today that Ryan Willemsen has been appointed Chief Commercialization Officer.
In this role, Willemsen will be responsible for leading market adoption of Flyte, building a global sales and distribution capability, establishing operational infrastructure to scale the growth of Pelvital, and helping to assure the financial wellbeing of the company. With more than 14 years of medical technology leadership experience, including 8 years in pelvic health, Willemsen has excelled at developing new markets, bringing new products to market, and leading successful commercial organizations.
“We are excited to welcome Ryan to the Pelvital team. His deep commercial experience and proven track record of executive leadership will help us develop the market for Flyte therapy and grow Pelvital to successfully help women treat, rather than cope with, stress urinary incontinence,” said Dale Wahlstrom, Co-Founder and CEO of Pelvital. “His success in both the traditional clinician and direct-to-consumer channels will be instrumental in driving the adoption of Flyte and creating a new first-line standard of care for effective, non-surgical treatment of female urinary incontinence.”
Willemsen’s 14 years of experience at Medtronic include executive leadership positions in marketing, strategy, business development and finance. While at Medtronic, Ryan developed and led strong teams to drive growth in new and developing global medical device markets.
“I am thrilled to join the Pelvital team at this important time and I look forward to helping lead the business to serve the needs of women coping with stress urinary incontinence,” said Willemsen. “I believe that women deserve safe, effective, clinically proven, FDA-approved, non-surgical and cost-effective products to treat common issues like stress urinary incontinence. Pelvital has a tremendous opportunity to improve the quality of life for millions of women through the simple and efficient at-home treatment of Flyte.”
Pelvital is a privately held medical technology company focused on women’s health. Pelvital’s vision is to significantly improve the lives of people who suffer from pelvic floor disorders through novel, easy-to-use products backed by strong clinical evidence. Founded in Minnesota in 2016 with roots in Norway, the company is focused on expanding conservative treatment options to inspire consumers to treat conditions rather than cope with symptoms.
Pelvital’s first product, Flyte, is a clinically proven, in-home treatment for stress urinary incontinence, designed to treat weakened pelvic floor muscles to reduce bladder leaks, restore continence and improve quality of life. For more information visit pelvital.com.